Clinical Trials | March 09, 2022
SRL Diagnostics report indicates women neglect routine tests
Routine tests undertaken by women dropped by 35% in 2020
Routine tests undertaken by women dropped by 35% in 2020
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Ind-Ra expects revenue growth of over 12% in 2022.
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Flattish volume growth and subdued new launches were key factors for last month
Healtherbs helps in restoring the desired energy levels for daily activity and immunity
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
Subscribe To Our Newsletter & Stay Updated
